A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
A phase 1/2 trial of Ifinatamab deruxtecan, Durvalumab in small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) is a phase 1/2 interventional study registered as NCT06780137 by Merck Sharp & Dohme LLC, with 327 participants planned, started 2025-02-27 and due to reach its primary completion in 2029-04-27. Interventions recorded: Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Small-cell lung cancer.
- TrialA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- TrialIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- TrialStudy of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).
- TrialA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).
- TrialA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, Small-cell lung cancer.
- TrialA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).